Compare Davita Inc (DVA) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs VF Corp — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while VF Corp trades at $16.55 (market cap $6.54B). The key difference: Davita Inc is far larger — about 2.3× VF Corp's market cap, and VF Corp pays a 2.16% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | VFC | |
|---|---|---|
Market Cap | $14.92B | $6.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $235.71 | $21.55 |
52-Week Low | $103.87 | $11.66 |
Enterprise Value | $27.47B | $10.69B |
Dividend Yield | — | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
VFC trades at $16.88, up 0.66% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Recent earnings show volatility with Q1 2026 missing estimates after previous beats. Revenue declined to $9.50B in 2025 with a net loss of $189.72M, though 2026 projects a return to profitability. The company maintains a solid gross margin of 54.78% and reduced debt-to-asset ratio to 42.42% in 2025.
Outlook hinges on execution of turnaround efforts, particularly brand performance at Vans. Analyst consensus is mixed with a $19.33 price target suggesting 14.5% upside, but weak consumer spending and competitive pressures pose near-term risks. Cash flow improvement in 2026 projections and continued deleveraging provide potential catalysts if operational trends stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
